The results of a large National Institute on Drug Abuse (NIDA) funded study comparing the outcomes of a monthly shot of naltrexone (sold as Vivitrol) vs a daily pill of buprenorphine and naloxone (sold as Suboxone) has been published. (See the study) At 6 months, about half of people with opioid use disorder who took either medication remained free from relapse. These results supported the findings of an smaller study.
This is good news for individuals who could benefit from medication assisted treatment, but have opted not to take Suboxone or Methadone because they are partial and full opioid agonists, meaning they are opioids with abuse and diversion potential.
There has been a misperception that Vivitrol does not work as well as other medication assisted treatment options, which hopefully this study dispels.
A barrier to Vivitrol becoming more readily available is its cost compared to other medication assisted treatment options.